Transfer of EBV-specific CTL to prevent EBV lymphoma post bone marrow transplant

✍ Scribed by Helen E. Heslop; Margot Perez; Ely Benaim; Richard Rochester; Malcolm K. Brenner; Cliona M. Rooney

• Book ID: 101260012
• Publisher: John Wiley and Sons
• Year: 1999
• Tongue: English
• Weight: 20 KB
• Volume: 14
• Category: Article
• ISSN: 0733-2459
• DOI: 10.1002/(sici)1098-1101(1999)14:3<154::aid-jca9>3.0.co;2-k

✦ Synopsis

EBV-associated lymphoproliferative disorders (EBV-LPD) are a significant problem after hemopoietic stem cell transplantation from unrelated donors or mismatched family members. Risk factors include T-cell depletion, MHC mismatch, and intensity of immunosuppression. New therapeutic strategies involve cellular immunotherapy approaches and both donor T-cells and EBV-specific cytotoxic T lymphocytes (CTLs) have proven to be effective therapies. EBV-specific CTL has also proved to have a major impact on the incidence of this complication when used prophylactically.